This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Emergent Biosolutions (EBS) Q2 Earnings Lag Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -25.00% and 14.21%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Emergent Biosolutions (EBS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Emergent (EBS) Wins HHS Contract to Supply VIGIV Product
by Zacks Equity Research
Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.
Why Is Emergent Biosolutions (EBS) Down 23.4% Since Last Earnings Report?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent (EBS) Earnings & Revenues Miss Estimates in Q1
by Zacks Equity Research
Emergent (EBS) incurs loss in the first quarter and misses on revenues as well.
New Strong Sell Stocks for May 3rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Emergent Biosolutions (EBS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -200.00% and -6.88%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Emergent Biosolutions (EBS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study
by Zacks Equity Research
Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.
Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth
by Zacks Equity Research
Emergent's (EBS) vaccine portfolio looks promising. The company's recent acquisitions also bode well for growth.
Emergent Biosolutions (EBS) Down 24.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent Begins Phase III Study on Anthrax Vaccine AV7909
by Zacks Equity Research
Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.
Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates
by Zacks Equity Research
Emergent (EBS) rides high on both earnings and a revenue beat in Q4.
Emergent Biosolutions (EBS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 22.95% and 0.63%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Emergent Biosolutions (EBS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.
Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed
by Zacks Equity Research
Emergent (EBS) names Robert G. Kramer, Sr. as its next chief executive officer, who will assume office from Apr 1, 2019 onward. He will succeed the incumbent CEO Daniel J. Abdun-Nabi.
Emergent (EBS) Files Application for Emergency Use of NuThrax
by Zacks Equity Research
Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.
Emergent Biosolutions (EBS) Up 14.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint
by Zacks Equity Research
Emergent BioSolutions (EBS) and partner Valneva present positive data from an early-stage study on the Zika vaccine candidate, VLA1601.
Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Emergent (EBS) disappoints with weaker-than-expected results in the third quarter of 2018.
Emergent Biosolutions (EBS) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -11.29% and -7.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Exelixis' (EXEL) third-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.
What's in Store for Sangamo (SGMO) This Earnings Season?
by Zacks Equity Research
On Sangamo's (SGMO) Q3 2018 conference call, investor focus will be on the company's progress with its genome editing and gene regulation technology platform.
What's in the Cards for Geron (GERN) This Earnings Season?
by Zacks Equity Research
In a major setback to Geron (GERN), J&J terminates collaboration for development of its sole pipeline candidate, imetelstat. Investor focus to remain on path forward for imetelstat.